secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001823239-25-000033
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%
--------------------------------------------------------------------------------

- Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.
- Q4 revenue $56.6M (-23.7% YoY); Adjusted EBITDA loss of $1.1M vs +$20.5M a year ago.
- Full year 2024 revenue $259.2M (-10.3% YoY); net loss $259.6M includes $166M goodwill impairment.
- Voluntarily prepaid $228M of Term Loan with cash; year-end cash $322M.
- Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/0001823239-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/mrvi-20250317.htm
  HTML page:      https://secwatch.observer/filing/0001823239-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer